Circulating microRNAs track early recovery after myocardial infarction
Myocardial infarction can set off a long remodeling cascade in which injured myocardium dilates, contracts less efficiently, and gradually moves toward heart failure. In a small pilot cohort, investigators searched for circulating microRNAs that might identify the subset of patients who move in the opposite direction: toward left ventricular reverse remodeling after infarction and rehabilitation.
The study focused on a clinically familiar but biologically slippery question. Some patients recover left ventricular function after an acute infarct, while others remain stuck with stable dysfunction despite reperfusion, optimal medical therapy, and cardiac rehabilitation. Because microRNAs regulate gene expression across inflammatory, fibrotic, proliferative, and stress-response pathways, they are plausible candidates for capturing that divergence early in the recovery process.
Twenty patients entered the final analysis. Ten met echocardiographic criteria for LVRR at 8-week follow-up, defined by an absolute left ventricular ejection fraction increase of at least 10% or a left ventricular end-systolic volume reduction of at least 15%, and ten had stable left ventricular status. Baseline testing occurred during hospitalization on day 3 after myocardial infarction, with follow-up after completion of a 4-week rehabilitation program.
Baseline function separated the two groups before recovery began
At baseline, the stable left ventricular status group already had better systolic function. Mean LVEF was 53% in the stable group versus 44% in the reverse-remodeling group, a statistically significant difference. That gap matters clinically because it suggests the patients who later improved started from a more injured state, which may be exactly where a biomarker of recovery carries the most value.
Regional wall motion also changed in a way that fits the remodeling phenotype. Baseline regional contractility impairment in all patients assigned to the reverse-remodeling group was reversed in 70% by follow-up. In practical bedside terms, the myocardium did not merely avoid further decline; a substantial fraction of injured segments regained measurable function over a short rehabilitation window.
The rehabilitation pathway itself was structured rather than casual. After discharge, all patients underwent a cardiac rehabilitation program with controlled physical activity, outpatient follow-up within the comprehensive care after myocardial infarction model, and exercise stress testing before and after the rehabilitation period. Training intensity and type were adjusted to cardiovascular risk and physical capacity, which means the recovery signal emerged in the context of standard post-infarction care rather than an experimental exercise strategy.
Fourteen candidate microRNAs clustered around stress-response signaling
From 375 circulating microRNAs measured by RT-qPCR, 14 emerged as candidate biomarkers associated with left ventricular reverse remodeling. The list included miR-15b-5p, miR-24-3p, miR-29c-3p, miR-99b-5p, miR-127-3p, miR-146a-5p, miR-199a-3p, miR-361-5p, miR-502-5p, miR-625-5p, miR-376c-3p, miR-18b-5p, miR-342-5p, and miR-429.
Three of those stand out as especially interesting because they represent the kind of candidate biomarkers that could move from mechanistic curiosity toward clinical enrichment tools: miR-502-5p, miR-376c-3p, and miR-18b-5p. None are ready for clinical use, but their appearance in the responder group expands the field beyond the more familiar remodeling-associated miRNAs already described in the literature.
Target-gene enrichment linked these candidates to PI3K-Akt, MAPK, FoxO, and HIF-1 signaling. Those pathways fit the biology of post-infarction recovery. PI3K-Akt and MAPK are central to cell survival, growth, and stress signaling; FoxO influences oxidative stress handling and apoptosis; HIF-1 connects to hypoxia adaptation and tissue-level responses to ischemia. In a damaged ventricle, the balance among these pathways helps determine whether the myocardium progresses toward scarring and dilation or shifts toward adaptive repair.
Why this biomarker signal is biologically plausible
The post-infarction heart does not remodel through one mechanism alone. Inflammation, fibrosis, hypertrophy, extracellular matrix turnover, and microvascular adaptation all interact, and microRNAs sit upstream of many of those processes because they can suppress or fine-tune multiple gene targets at once. A small panel of circulating miRNAs may therefore function as a biochemical snapshot of whether the ventricle is still locked in injury mode or has begun to re-enter a recovery program.
The study design also supports the biologic interpretation. Blood sampling and echocardiography were performed at baseline and again after rehabilitation under the same conditions, reducing some of the noise that often clouds early biomarker work. Even so, this remained a pilot effort with a pooled final sample of 20 analyzed patients, so the signal is hypothesis-generating rather than practice-changing.
What the pilot can and cannot claim
The study establishes a shortlist of candidate biomarkers for reverse remodeling after myocardial infarction, not a validated clinical test. The cohort was small, single-center, and highly selected: all patients had a first myocardial infarction, successful reperfusion with direct PCI, no chronic total occlusion, and no history of conditions such as atrial fibrillation, severe renal or hepatic dysfunction, acute inflammation, or neoplastic disease.
That narrow selection reduces biological confounding but also limits generalizability. Patients with more complex infarct histories, ongoing arrhythmia, competing systemic illness, or unsuccessful reperfusion were not represented. The eight-week time horizon is another constraint. Reverse remodeling is dynamic, and a biomarker signature that distinguishes early recovery may not perform the same way at later time points or in broader post-MI populations.
Even with those limits, the clinical logic is strong. If a circulating miRNA panel can identify patients most likely to reverse remodel after infarction, clinicians could one day use that information to refine post-MI risk assessment, personalize rehabilitation intensity, and track molecular recovery alongside echocardiography. For now, the main finding is more modest and more important: a measurable plasma signature emerged in patients whose ventricles improved, and that signature mapped onto canonical survival and hypoxia-response pathways.
The next step is validation in larger, non-pooled cohorts before any of these miRNAs can be treated as actionable biomarkers at the bedside.